About Bridge TherapeuticsBridge Therapeutics®, based in Birmingham, Ala., is an innovative development-stage specialty pharmaceutical company pursuing U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals of a patented (U.S. Patent #8410092) drug combination, BT-205, for the treatment of chronic pain in opioid-experienced patients. The investigational drug BT-205 is a unique combination of two synergistic chronic pain drugs—the partial-agonist opioid buprenorphine and the NSAID meloxicam—delivered in a state-of-the-art sublingual formulation. The dosing and delivery method will be a commercial advantage over the current alternatives. Bridge Therapeutics' goal is to make the BT-205 compound and other investigational new drug candidates available to millions of patients in which addictive and potentially dangerous full-agonist opioids such as oxycodone and morphine are ineffective and/or unsatisfactory.
CEO: Dr. Greg Sullivan
4 articles with Bridge Therapeutics
Bridge Biotherapeutics Enters AI-based Research Collaboration with Atomwise to Expand Pellino Inhibitor Pipeline
Atomwise , the leader in using artificial intelligence (AI) for small molecule discovery, and Bridge Biotherapeutics (KOSDAQ: 288330), a clinical stage biotech company, announced today a research collaboration to launc
Bridge Therapeutics Announces It Will Seek FDA Approval for BT-219, a Treatment for Opioid Dependence in the Coming Months
Bridge Therapeutics Inc. announced that it has received feedback from the Food and Drug Administration from a Pre-Investigational New Drug meeting for the development of BT-219, a therapy to treat Opioid Dependence.
Bridge Therapeutics, an innovative startup pharmaceutical company developing a practical and safe therapy for chronic pain, is pleased to announce the addition of Edward J. Minskoff to its board of directors.